L-beta-高丝氨酸 | 589-44-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丝氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-beta-高丝氨酸
• 中文别名: L-β-高丝氨酸；L-BETA-高丝氨酸；D-BETA-高丝氨酸
• 英文名称: (R)-3-amino-4-hydroxybutanoic acid
• 英文别名: (3R)-3-azaniumyl-4-hydroxybutanoate
• CAS: 589-44-6；16504-55-5；16504-56-6；16504-57-7
• 化学式: C₄H₉NO₃
• 分子量: 119.12
• InChiKey: BUZICZZQJDLXJN-GSVOUGTGSA-N

物化性质

• 沸点：
  374.5±32.0 °C(Predicted)
• 密度：
  1.312±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090
• 危险性防范说明：
  P264,P280,P305+P351+P338,P337+P313
• 危险性描述：
  H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: D-Beta-homoserine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: D-Beta-homoserine
CAS number: 16504-57-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H9NO3
Molecular weight: 119.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  L-beta-高丝氨酸 生成 (R)-3-(benzyloxycarbonylamino)-4-(tert-butyldimethylsilyloxy)butanoic acid
  参考文献：
  名称：

  TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS

  摘要：

  Provided are compounds of formula (I), (Ia), (Ib), and (Ic), and pharmaceutically and/or cosmeceutically acceptable salts thereof. Additionally provided are pharmaceutical and/or cosmeceutical compositions and formulations, comprising the compounds and/or salts thereof, therapeutic and/or cosmetic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP)/β-catenin mediated signaling in treating skin related diseases, conditions or disorders (e.g., dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP/β-catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.) mediated by aberrant CBP/β-catenin signaling.

  公开号：

  US20220106320A1
• 作为产物：
  描述：

  (R)-3-(((benzyloxy)carbonyl)amino)-4-methoxy-4-oxobutanoic acid 生成 L-beta-高丝氨酸
  参考文献：
  名称：

  通过1-或4-羧基连接的天冬氨酸的D-葡萄糖基酯的合成和重排。

  摘要：

  2,3,4,6-四-O-苄基-1-O- [1-苄基N-（苄氧羰基）-L-天冬氨酸-4-酰基]-α-D-吡喃葡萄糖（1alpha）的催化加氢酸-2-甲氧基乙醇得到被2-O-（L-α-天冬氨酰）-D-吡喃葡萄糖污染的1-O-（L-β-天冬氨酰）α-D-吡喃葡萄糖（2α）（8）。从1alpha的1-oyl异构体形成8的证据，即2,3,4,6-四-O-苄基-1-O- [4-苄基N-（苄氧羰基）-L-天冬氨酸1-oyl通过使脱保护的D-葡糖基酯连续进行N-乙酰化，酯化和O-乙酰化，得到1个导致2个酰基迁移的]-α-D-吡喃葡萄糖（7α）；最终产物经鉴定为2,3,4,6-四-O-乙酰基-1-O- [1-甲基N-（乙酰基）-L-天冬氨酸4-酰基]-的约4：1混合物α-D-吡喃葡萄糖（4alpha）和1,3,4 也通过确定方法制备的6-四-O-乙酰基-2-O- [4-甲基N-（乙酰基）-L-天冬氨酸-1-基]

  DOI：

  10.1016/s0008-6215(00)83546-6

文献信息

• [EN] 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS<br/>[FR] COMPOSÉS 4-HYDROXY-ISOQUINOLÉINE COMME INHIBITEURS D'HYDROXYLASE HIF
  申请人：FIBROGEN INC

  公开号：WO2013134660A1

  公开（公告）日：2013-09-12

  The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.

  本发明涉及式(I)的新化合物，以及能够选择性地抑制PHD1酶活性而不影响其他同工酶（例如PHD2和/或PHD3酶）的组合物。该发明还涉及式(I)的化合物在肌肉退化、结肠炎、炎症性肠病和某些缺血症等疾病中的应用。
• [EN] BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] DÉRIVÉ DE BENZYLAMINE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 苄胺类衍生物及其制备方法与用途
  申请人：ACAD OF MILITARY MEDICAL SCIENCES

  公开号：WO2022033303A1

  公开（公告）日：2022-02-17

  涉及苄胺类衍生物及其制备方法与用途。具体涉及通式(Ⅰ)所示的苄胺类衍生物，或其药学上可接受的立体异构体、盐、溶剂化物或前药，其与人PD-L1有很强的结合能力，能明显抑制PD-1/PD-L1相互作用，具有显著地体内抗肿瘤药效。因此，还涉及所述苄胺类衍生物的制备方法及其在制备治疗与PD-1/PD-L1相关疾病的药物中的用途，
• Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo
  作者：Jialin Guo、Longlong Luo、Zhihong Wang、Naijing Hu、Wei Wang、Fei Xie、Erguang Liang、Xinlin Yan、Junhai Xiao、Song Li

  DOI：10.1021/acs.jmedchem.0c01329

  日期：2020.11.25

  A series of novel linear aliphatic amine-linked triaryl derivatives as inhibitors of PD-1/PD-L1 were designed, synthesized, and evaluated in vitro and in vivo. In this chemical series, compound 58 showed the most potent inhibitory activity and binding affinity with hPD-L1, with an IC50 value of 12 nM and a KD value of 16.2 pM, showing a binding potency approximately 2000-fold that of hPD-1. Compound

  设计，合成和评估了一系列新颖的线性脂肪族胺连接的三芳基衍生物作为PD-1 / PD-L1的抑制剂。在该化学系列中，化合物58与hPD-L1表现出最强的抑制活性和结合亲和力，IC 50值为12 nM，KD值为16.2 pM，结合力约为hPD-1的2000倍。化合物58可与细胞表面上的hPD-L1结合并竞争性阻断hPD-1与hPD-L1的相互作用。在T细胞功能测定中，58恢复了T细胞功能，导致IFN-γ分泌增加。此外，在人源化小鼠模型中，化合物58静脉注射后可显着抑制肿瘤生长而无明显毒性，并表现出中等的PK特性。这些结果表明58是进一步开发用于癌症治疗的小分子PD-1 / PD-L1抑制剂的有希望的先导。
• Anticoagulant peptide alcohols
  申请人：Merrell Dow Pharmaceuticals

  公开号：US04971953A1

  公开（公告）日：1990-11-20

  This invention relates to peptide derivatives which are useful anticoagulant agents.

  这项发明涉及肽衍生物，它们是有用的抗凝剂。
• Fluorescent Labeled Sphingosines
  申请人：Billich Andreas

  公开号：US20080318255A1

  公开（公告）日：2008-12-25

  The present invention relates to a method (assay) for determining the activity of an enzyme selected from the group consisting of a sphingosine kinase and a phosphatase involved in the sphingolipid pathway by use of a labeled sphingosine.

  本发明涉及一种方法（测定法），通过使用标记的鞘氨醇来确定从一组中选择的鞘脂途径中涉及的鞘氨醇激酶和磷酸酶的活性。